Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases

被引:36
|
作者
Serreau, R
Luton, D
Macher, MA
Delezoide, AL
Garel, C
Jacqz-Aigrain, E
机构
[1] Hop Robert Debre, Ctr IMAGE, Dept Pediat Pharmacol & Pharmacogenet, F-75019 Paris, France
[2] Hop Robert Debre, Dept Obstet & Gynaecol, F-75019 Paris, France
[3] Hop Robert Debre, Dept Pediat Nephrol, F-75019 Paris, France
[4] Hop Robert Debre, Dept Foetopathol, F-75019 Paris, France
[5] Hop Robert Debre, Dept Radiol, F-75019 Paris, France
关键词
D O I
10.1111/j.1471-0528.2004.00525.x
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective Angiotensin II type I receptor antagonists (ARA). Interacted with the renin-angiotensin system, and the present study was undertaken to examine their fetal and neonatal toxicity when taken by the mother during pregnancy. Design Prospective follow up of pregnant women exposed to an ARA during early pregnancy. Setting The present study was conducted in the departments of Paediatric Pharmacology of the University hospital Robert Debre in Paris, France. Population Ten women exposed to an ARA during early pregnancy. Methods Prospective follow up. Main outcome measure Fetal ultrasonography and outcome of pregnancy. Results Prenatal ultrasonography showed abnormal features in five cases (oligoamnios related to fetal tabular dysgenesis, fetal dysmorphia and renal abnormalities). Outcome of pregnancy was as follows: three induced abortions, two stillbirths (twin pregnancy), one neonate presenting with dysmorphia and renal disease and five neonates with an uneventful development. Conclusion Women of reproductive age should be advised of the possible hazards of ARA and treatment should be stopped as soon as pregnancy has been documented.
引用
收藏
页码:710 / 712
页数:3
相关论文
共 50 条
  • [21] Comparison of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Essential Hypertension
    David H. G. Smith
    Drugs, 2008, 68 : 1207 - 1225
  • [22] Molecular activation of PPARγ by angiotensin II type 1-receptor antagonists
    Erbe, David V.
    Gartrell, Katherine
    Zhang, Yan-Ling
    Suri, Vipin
    Kirincich, Steven J.
    Will, Sarah
    Perreault, Mylene
    Wang, Suyue
    Tobin, James F.
    VASCULAR PHARMACOLOGY, 2006, 45 (03) : 154 - 162
  • [23] The Role of Angiotensin II Type 1 Receptor Antagonists in Elderly Patients with Hypertension
    G. Neil Thomas
    Paul Chan
    Brian Tomlinson
    Drugs & Aging, 2006, 23 : 131 - 155
  • [24] Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist
    Fujimoto, Y
    Sasaki, T
    Tsuchida, A
    Chayama, K
    FEBS LETTERS, 2001, 495 (03) : 197 - 200
  • [25] Angiotensin II receptor antagonists against migraine in pregnancy: fatal outcome
    Kirsti Haaland
    The Journal of Headache and Pain, 2010, 11 : 167 - 169
  • [26] Angiotensin II receptor antagonists against migraine in pregnancy: fatal outcome
    Haaland, Kirsti
    JOURNAL OF HEADACHE AND PAIN, 2010, 11 (02): : 167 - 169
  • [27] Angiotensin type 1 receptor antagonists induce PPARgamma activation in human adipose
    Janke, J
    Schupp, M
    Engeli, S
    Gorzelniak, K
    Said, L
    Nystrom, FH
    Luft, FC
    Sharma, AM
    HYPERTENSION, 2005, 46 (04) : 823 - 823
  • [28] Translational regulation of the human angiotensin II type 1 receptor
    Elton, TS
    Zhao, X
    Martin, MM
    FASEB JOURNAL, 1999, 13 (07): : A1471 - A1471
  • [29] ANGIOTENSIN II RECEPTOR TYPE 1 NOT DETECTED ON HUMAN LYMPHOCYTES
    Li, M.
    McDougan, F.
    Kimball, P.
    HUMAN IMMUNOLOGY, 2021, 82 : 159 - 159
  • [30] Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists-A perspective
    Naik, Prashant
    Murumkar, Prashant
    Giridhar, Rajani
    Yadav, Mange Ram
    BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (24) : 8418 - 8456